Filtered By:
Source: Herz
Condition: Bleeding

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 29 results found since Jan 2013.

Surgical vs. drug therapy in patients with patent foramen ovale and cryptogenic stroke.
CONCLUSION: Compared with drug therapy, PFO closure reduced the risk of recurrent stroke among patients with a risk score of ≥2 and reduced the incidence of serious bleeding without increasing the risk of new-onset atrial fibrillation or atrial flutter. PMID: 32394019 [PubMed - as supplied by publisher]
Source: Herz - May 14, 2020 Category: Cardiology Tags: Herz Source Type: research

Stroke prophylaxis in atrial fibrillation : When, how and for whom?
This article provides a review of the indications and contraindications of modern stroke prophylaxis and discusses the approach to frequent clinical scenarios, such as treatment of patients with an acute coronary syndrome, coronary stent intervention or catheter ablation of AF. PMID: 28439617 [PubMed - as supplied by publisher]
Source: Herz - April 26, 2017 Category: Cardiology Tags: Herz Source Type: research

Closure of the patent foramen ovale (PFO) in cryptogenic stroke.
Authors: Diener HC, Knebel F Abstract Autopsy studies and echocardiographic investigations have shown that around 20-25% of the healthy population have a patent foramen ovale (PFO). In patients younger than 55 years the risk of a cryptogenic stroke is increased in the presence of a PFO. The first three randomized studies could not demonstrate superiority of an interventional closure of a PFO compared to antithrombotic treatment in patients with cryptogenic stroke. The results of three recently published studies and the extension of an earlier study showed a superiority of an interventional closure of a PFO comp...
Source: Herz - April 5, 2019 Category: Cardiology Tags: Herz Source Type: research

Left atrial appendage closure for stroke prevention in atrial fibrillation : An update.
Authors: Zimmermann F, Landmesser U Abstract Atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke. Without treatment the annual risk of ischemic stroke is on average approximately 5-6%/year in patients with atrial fibrillation, depending on the overall cardiovascular risk profile. Oral anticoagulation with new oral anticoagulants (NOAC) or vitamin K antagonists (VKA) is recommended for patients with AF and an elevated risk for stroke (CHA2DS2-VASc score ≥1); however, severe bleeding complications are potential reasons for discontinuation of this treatment. Overall, up to 30 % of the pa...
Source: Herz - May 18, 2020 Category: Cardiology Tags: Herz Source Type: research

Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment : A meta-analysis.
CONCLUSION: Our analysis found no statistically significant difference between TT and DT with regard to all-cause death and MACE/stroke risk. At the same time, the available data demonstrated that TT increased the risk of major bleeding. If the international normalized ratio is in the target range, the risk of bleeding may be lowered. The data from Asian countries were limited, and therefore we could not assess the difference between TT and DT in Asian populations. Finally,on the basis of our analysis, we do not recommend TT as conventional treatment for patients taking OACs and undergoing percutaneous coronary interventio...
Source: Herz - July 3, 2015 Category: Cardiology Tags: Herz Source Type: research

Antithrombotic treatment in acute coronary syndrome and atrial fibrillation.
Authors: Darius H, Görge G, Spiecker M, Schinzel H Abstract The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and indications for oral anticoagulation (OAC) for the prevention of stroke, who need dual antiplatelet treatment (DAPT) with acetylsalicylic acid (ASA) plus a P2Y12 inhibitor because of an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is also increasing. In the past these patients received a triple therapy (TT) for 3-12 months. This TT has never been studied for efficacy; how...
Source: Herz - January 30, 2019 Category: Cardiology Tags: Herz Source Type: research

Left atrial appendage closure after cryoballoon ablation in patients with atrial fibrillation.
CONCLUSION: The intraprocedural combination of CBA and LAAC is feasible in patients with non-valvular AF with a high risk of stroke, TIA, and/or bleeding. Larger long-term randomized studies are needed to judge the overall safety and efficacy of the combined procedure. PMID: 32002565 [PubMed - as supplied by publisher]
Source: Herz - February 1, 2020 Category: Cardiology Tags: Herz Source Type: research

New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a  meta-analysis.
CONCLUSION: The findings show that NOACs are effective and safe for preventing stroke/SE in patients with both NVAF and PAD. PMID: 32728781 [PubMed - as supplied by publisher]
Source: Herz - August 1, 2020 Category: Cardiology Tags: Herz Source Type: research

Left atrial appendage closure : Current data and future developments
Herz. 2021 Aug 31. doi: 10.1007/s00059-021-05065-8. Online ahead of print.ABSTRACTCatheter-based left atrial appendage closure (LAAC) is currently a potential treatment option for stroke prevention in patients with atrial fibrillation and high risk for stroke/embolism as well as high bleeding risk. Due to improvements in LAAC devices, advances in implantation techniques and growing experience of the interventional teams, the safety profile of LAAC has significantly improved in recent years. These developments have led to a currently comprehensive exploration of novel indications for LAAC, such as patients with atrial fibri...
Source: Herz - August 31, 2021 Category: Cardiology Authors: Carsten Skurk Claudio Seppelt Denitsa Meteeva Markus Rheinthaler Ulf Landmesser Source Type: research

Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.
Authors: Erath JW, Hohnloser SH Abstract Atrial fibrillation (AF) is the most frequently encountered sustained arrhythmia with a prevalence of 0.5-10%, depending predominantly on age. The arrhythmia is associated with significant morbidity and mortality, mainly due to thromboembolic events including stroke and systemic embolisms. These complications can be effectively prevented with anticoagulation therapy either with vitamin K antagonists (VKA) or with non-vitamin K antagonists (NOAC). VKA therapy is effective in preventing strokes but these medications are difficult to use, are associated with significant blee...
Source: Herz - November 19, 2017 Category: Cardiology Tags: Herz Source Type: research

Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?
Authors: Bahrmann P, Christ M Abstract Based on established risk scores, such as the CHA2DS2-VASc score, the indications for oral anticoagulation are given for patients over 65 years old with atrial fibrillation and even more so for patients over 75 years old. Before beginning anticoagulation a geriatric assessment for evaluation of the cognitive ability, the activities of daily living and the risk of falling should be made because of the known complications of anticoagulation. Geriatric patients with non-valvular atrial fibrillation (AF) are increasingly being treated with non-vitamin K antagonist oral anticoagul...
Source: Herz - December 22, 2017 Category: Cardiology Tags: Herz Source Type: research

Real-world analysis of a Biolimus A9 polymer-free drug-coated stent with very short dual antiplatelet therapy in patients at high bleeding risk.
CONCLUSION: In real-world patients at high risk of bleeding, implantation of the polymer-free metallic stent coated with Biolimus-A9 (Biofreedom®; Biosensors Europe, Morges, Switzerland) followed by 1 -month DAPT showed encouraging results without any stent thrombosis. PMID: 31965195 [PubMed - as supplied by publisher]
Source: Herz - January 24, 2020 Category: Cardiology Tags: Herz Source Type: research

Therapeutic management of nonvalvular atrial fibrillation.
Authors: Gunawardene MA, Hartmann J, Jularic M, Eickholt C, Gessler N, Willems S Abstract Atrial fibrillation (AF) is the most frequent persistent cardiac arrhythmia and is associated with an increased mortality. Therefore, an effective differential treatment of patients is mandatory. After a risk stratification oral anticoagulation (OAC) should be initiated depending on the individual stroke risk of each patient. Alternatively, in the presence of contraindications for OAC and an increased risk for bleeding and/or stroke, the implantation of a left atrial appendage closure device can be considered. Symptomatic pati...
Source: Herz - July 9, 2020 Category: Cardiology Tags: Herz Source Type: research

Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation.
Authors: Hohnloser SH Abstract Non-vitamin K oral anticoagulants (NOAC) have now become established for stroke prevention in atrial fibrillation. The efficacy is at least as good if not better than that of vitamin K antagonists (VKA). The risk for major bleeding is less for NOAC than for VKA, with a particular superiority concerning the avoidance of intracerebral hemorrhage. The outcome after major bleeding is more favorable in patients receiving NOAC compared to those treated with VKA. Specific reversal agents for NOAC are currently being tested which neutralize the effects of NOAC within minutes and the clinical ...
Source: Herz - December 18, 2015 Category: Cardiology Tags: Herz Source Type: research

Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation : Systematic analysis of a single-center experience.
CONCLUSION: Only the echocardiographic and epidemiologic parameters were predictors of left atrial thrombi and SEC intensity, while the studied biomarkers had no predictive power. Using clinical data and transthoracic echocardiography, we can change the therapeutic strategy in high-risk patients. PMID: 27100878 [PubMed - as supplied by publisher]
Source: Herz - April 23, 2016 Category: Cardiology Tags: Herz Source Type: research